Unfortunately (for me) I agree with your assessment. Still the volume was way up today, presumably on this announcement. I would be deeply appreciative if you would share your thoughts on it...thanks!
Tuesday November 4 8:29 AM EST
Company Press Release
Cambridge NeuroScience Receives Drug Delivery Device Patent for Sustained, Controlled Release of Large Molecules
CAMBRIDGE, Mass., Nov. 4 /PRNewswire/ -- Cambridge NeuroScience, Inc. (Nasdaq:CNSI) today announced that it has been issued U.S. patent 5,681,568 for a device for the controlled release of large molecules such as proteins, antibodies, enzymes, hormones and vaccines. The device offers many advantages over existing products including: high surface to volume ratio that offers greater release capacity; protection of the integrity of the large molecules; selective targeting of the therapeutic agents, which limits toxicity by releasing the agent only in specific amounts at specific times; and the ability to construct the device into several forms, such as transdermal patches or dissolving implants.
''We are delighted to receive issuance of this broad patent that allows for sustained release of growth factors and a variety of other therapeutic agents,'' said Gregory Butler, Ph.D., Vice President Legal Affairs and Intellectual Property at Cambridge NeuroScience. ''The patent includes claims directed to the device itself, methods of using the device, and methods for making the device.''
''This patent allows for the possibility of delivering large protein molecules directly to those parts of the nervous system that need them to promote recovery or regrowth,'' said Elkan R. Gamzu, Ph.D., President and Chief Executive Officer at Cambridge NeuroScience. ''Treatment of nervous system diseases is our mandate, but we see broad applications in areas such as oncology or hormone replacement, where we hope to form alliances with other companies to capitalize on this new technology.''
Cambridge NeuroScience, Inc. is a leading neuroscience company engaged in the discovery and development of proprietary pharmaceuticals focusing on nerve cell survival. The Company is developing a number of products to treat stroke, traumatic brain injury and chronic neurodegenerative disorders such as multiple sclerosis, peripheral neuropathies and other degenerative diseases.
This press release contains forward-looking statements based on the current expectations of management. There are certain important factors that could cause results to differ from those anticipated by the statements made above, including, but not limited to, the ability of patents obtained by Cambridge NeuroScience to protect the Company's technology and provide a competitive advantage, the results of the scientific research and development programs described above, the strategic interests of Cambridge NeuroScience in pursuing its program as well as the results of future clinical trials, and the acceptance by regulatory authorities of the Company's clinical trial outcomes as a basis for marketing approval. |
